Fabrice André is a medical oncologist working at the Gustave Roussy Institute, Villejuif, France. He is involved in the development of targeted agents in breast cancer including mTOR inhibitors, FGFR inhibitors, PI3K inhibitors, CHK1 inhibitors. He is leading several academic prospective clinical trials that aim at developing personalized medicine for cancer treatment. He is also interested in symptom management and chairs a large epidemiological cohort of 20 000 women with breast cancer. In addition to his clinical research activity, he is chairing a translational research unit focused on biomarker development in several disease areas.